Media stories about Paratek Pharmaceuticals (NASDAQ:PRTK) have been trending somewhat negative on Friday, Alpha One Sentiment Analysis reports. The research group, a unit of Accern, identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Paratek Pharmaceuticals earned a news impact score of -0.05 on Alpha One’s scale. Alpha One also assigned media headlines about the specialty pharmaceutical company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected AlphaOne Sentiment Analysis’s rankings:
- Paratek Pharmaceuticals, Inc. (PRTK) is at $22.00 per share and … – Stocks Gallery (stocksgallery.com)
- ETFs with exposure to Paratek Pharmaceuticals, Inc. : June 15, 2017 (finance.yahoo.com)
- Paratek Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PRTK) : June 14, 2017 (finance.yahoo.com)
- Paratek Pharmaceuticals, Inc. to Participate in JMP Securities Life Science Conference – Nasdaq (nasdaq.com)
Several equities research analysts recently commented on PRTK shares. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 price objective on the stock in a research note on Thursday, April 20th. Robert W. Baird reaffirmed a “positive” rating and issued a $40.00 target price on shares of Paratek Pharmaceuticals in a report on Monday, March 27th. Guggenheim reaffirmed a “buy” rating on shares of Paratek Pharmaceuticals in a report on Monday, March 27th. Raymond James Financial, Inc. started coverage on shares of Paratek Pharmaceuticals in a report on Thursday, May 18th. They issued a “strong-buy” rating and a $36.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $32.00 target price on shares of Paratek Pharmaceuticals in a report on Thursday, March 30th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Paratek Pharmaceuticals currently has an average rating of “Buy” and an average target price of $36.80.
Paratek Pharmaceuticals (NASDAQ PRTK) traded up 2.27% on Friday, hitting $22.50. 1,215,085 shares of the stock traded hands. The firm has a 50-day moving average price of $21.61 and a 200-day moving average price of $17.72. The company’s market capitalization is $618.41 million. Paratek Pharmaceuticals has a 12 month low of $9.80 and a 12 month high of $25.00.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.06. The firm had revenue of $0.02 million for the quarter.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/06/16/paratek-pharmaceuticals-prtk-earns-news-sentiment-rating-of-0-05-updated-updated.html.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.